United States · Platforms & data · Morningstar

Akamis Bio to Present Data from a Phase 1 Study of NG-348 in Patients with Advanced Epithelial Tumors at SITC 2026

Published by Morningstar · United States 18 h ago

Akamis Bio to Present Data from a Phase 1 Study of NG-348 in Patients with Advanced Epithelial Tumors at SITC 2026 Akamis Bio, a clinical-stage oncology company working to advance…

Read the full article on Morningstar Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)

Also worth reading

MarketBeat

Needham & Company LLC Issues Pessimistic Forecast for Cipher Mining (NASDAQ:CIFR) Stock Price

Seeking Alpha

Revvity rises on full-year guidance boost

The Motley Fool

Warren Buffett Has 1 Simple Rule for Investing During Bear Markets. History Says He's Right.

CNBC

Stock market after midterm elections: What S&P 500 history shows

Benzinga

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

MarketWatch